Scholar Rock Holding Stock Price, News & Analysis

Scholar Rock (NASDAQ: SRRK) announced the initiation of Part B of the DRAGON Phase 1 trial for SRK-181, a TGFβ1 inhibitor, following supportive results from Part A. The trial aims to overcome resistance to anti-PD-(L)1 therapies in patients with advanced solid tumors. Initial data revealed no dose-limiting toxicities, and preliminary efficacy results showed stable disease in several patients. Part B will include multiple tumor cohorts, with early efficacy data expected in 2022.

Scholar Rock (NASDAQ: SRRK) reported Q3 2021 results, revealing a net loss of $37.5 million ($1.02 per share), up from a loss of $23.6 million ($0.79) a year earlier. Revenue reached $5.5 million, driven by a collaboration with Gilead. Key updates include the upcoming initiation of a Phase 3 trial for apitegromab in non-ambulatory Type 2 and 3 SMA patients and progress in the DRAGON trial for SRK-181. Additionally, a U.S. patent for SRK-181 extends protection to May 2040, enhancing its market position.

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on serious diseases, announced its participation in several upcoming investor conferences. On November 9, it will present at the Credit Suisse Virtual Healthcare Conference, followed by the Cowen IO Next Virtual Summit on November 15. The company will also attend the Jefferies Global Healthcare Conference in London on November 17 and the Piper Sandler Virtual Healthcare Conference from November 30 to December 2. Webcasts of the presentations will be available on the company's website.

Scholar Rock (NASDAQ: SRRK) has announced an e-poster presentation of clinical results from the TOPAZ Phase 2 trial of apitegromab for Type 2 and 3 spinal muscular atrophy (SMA) during the 25th World Congress of Neurology (WCN) from October 3-7, 2021. The presentation shows positive correlations between serum levels of latent myostatin and motor function improvements. Apitegromab is a selective myostatin inhibitor with FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations, but its efficacy and safety have yet to be established.

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company, announces a late-breaking poster presentation at the 50th Child Neurology Society Annual Meeting held from September 29 to October 2, 2021, in Boston. The presentation focuses on the efficacy of Apitegromab in patients with later-onset Spinal Muscular Atrophy (SMA) Types 2 and 3, highlighting responder analyses from the Phase 2 TOPAZ study. The poster will be published in the 2021 Annals of Neurology supplement. Apitegromab has received multiple designations from the FDA and EMA, although its efficacy and safety are not yet established.

Scholar Rock (NASDAQ: SRRK) announced the issuance of U.S. Patent No. 11,130,803, expiring May 2040, for SRK-181, a selective TGFβ1 inhibitor aimed at treating patients resistant to checkpoint inhibitors like anti-PD-(L)1 therapies. This patent fortifies the company's intellectual property as it progresses in the DRAGON Phase 1 trial, which focuses on safety and effectiveness in various solid tumor types. Initial clinical data from the trial is expected by year-end, reinforcing Scholar Rock's commitment to developing innovative cancer treatments.

Scholar Rock (NASDAQ: SRRK) recently presented two posters at the World Muscle Society Virtual Congress from September 20-24, 2021. The presentations highlighted findings from the TOPAZ Phase 2 trial of apitegromab for treating Spinal Muscular Atrophy (SMA). Key results include improvements in various efficacy endpoints such as Hammersmith scales and Revised Upper Limb Module (RULM) scores among patients. This research supports the potential of apitegromab and sets the stage for a Phase 3 trial aimed at establishing it as a leading muscle-directed therapy for SMA by year-end 2021.

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company, has announced its upcoming presentation at the 2021 Cantor Virtual Global Healthcare Conference on September 29 at 11:20 a.m. ET. This event marks an opportunity for the company to showcase its innovative approach in treating serious diseases through targeted protein growth factors. Interested parties can access the live webcast via the Scholar Rock website, with an archived replay available for 90 days post-event.

Scholar Rock (NASDAQ: SRRK) announces the appointment of Caryn Parlavecchio as the new Chief Human Resources Officer. With over 20 years of experience in the biotechnology and pharmaceutical sectors, she will enhance the company's HR strategies and talent acquisition efforts. Interim CEO Nagesh Mahanthappa emphasized that her insights will be pivotal for Scholar Rock's growth as it moves towards late-stage development and commercialization. Parlavecchio previously served at Holy Name Medical and held significant roles at Novartis.